昆德尔奥索诊断
QDEL
12.91
-1.00
-7.19%
昆德尔奥索诊断
US · QDEL
#3374 按市值排名
12.91
-1.00
-7.19%
实时 - 追踪5344个代码 - 心跳于166秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了0.5个百分点。
机构持股
- 机构持股比例
- 121.76% -0.50pp
- 机构数量
- 286
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund94.29%
Hedge Fund21.54%
Public Company3.51%
Individual/Insider1.12%
Government Pension Fund0.97%
Private Company0.84%
Insurance Company0.34%
Family Office/Trust0.22%
主要股东 截至 2026-06-30
BlackRock
16.34% · 11.20M 股
FMR
10.73% · 7.36M 股
Newtyn Management, LLC
9.66% · 6.63M 股
Vanguard Portfolio Management, LLC
6.03% · 4.14M 股
Vanguard Capital Management, LLC
5.14% · 3.52M 股
Neuberger Berman Investment Advisers LLC
4.93% · 3.38M 股
American Century Investment Management
4.82% · 3.31M 股
Rubric Capital Management LP
4.82% · 3.31M 股
Invesco Ltd.
4.48% · 3.07M 股
State Street Global Advisors
4.34% · 2.98M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 43次买入 · 7次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Douglas Bryant | Chief Executive Officer | 0.17% |
| Kenneth Buechler | Independent Non-Executive Chairperson | 0.16% |
| Brian Blaser | President | 0.11% |
| Joseph Busky | Chief Financial Officer | 0.08% |
| Matthew Strobeck | Independent Director | 0.07% |
| Robert Bujarski | Chief Operating Officer | 0.07% |
| Kenneth Widder | Independent Director | 0.07% |
| Michelle Hodges | General Counsel | 0.06% |
| Mary Polan | Independent Director | 0.06% |
| Edward Michael | Independent Director | 0.04% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | Ronald Bowman | Chief Human Resources Officer | Derivative Exercise and Sale | -921 | $10.63 |
| 2026-09-14 | Ronald Bowman | Chief Human Resources Officer | Derivative Exercise and Retained | +1,645 | -- |
| 2026-08-14 | Bryan Hanson | Senior Vice President of Clinical Labs & Transfusion Medicine | Derivative Exercise and Sale | -162 | $14.30 |
| 2026-08-14 | Bryan Hanson | Senior Vice President of Clinical Labs & Transfusion Medicine | Derivative Exercise and Retained | +284 | -- |
| 2026-07-14 | Micah Young | Chief Financial Officer & Principal Financial Officer | Other Derivative Acquisition | +356,555 | -- |
| 2026-06-30 | Bryan Hanson | Senior Vice President of Clinical Labs & Transfusion Medicine | Derivative Exercise and Sale | -2,096 | $18.18 |
| 2026-06-30 | Bryan Hanson | Senior Vice President of Clinical Labs & Transfusion Medicine | Derivative Exercise and Retained | +3,701 | -- |
| 2026-06-24 | Ann Rhoads | Independent Director | Other Derivative Acquisition | +369 | -- |
| 2026-06-24 | Ann Rhoads | Independent Director | Other Derivative Acquisition | +3,698 | -- |
| 2026-06-24 | Ann Rhoads | Independent Director | Other Derivative Acquisition | +15,532 | -- |
| 2026-06-24 | Kenneth Widder | Independent Director | Other Derivative Acquisition | +1,997 | -- |
| 2026-06-24 | Kenneth Widder | Independent Director | Other Derivative Acquisition | +6,656 | -- |
| 2026-06-24 | Kenneth Widder | Independent Director | Other Derivative Acquisition | +15,532 | -- |
| 2026-06-24 | Kenneth Buechler | Independent Non-Executive Chairperson | Other Derivative Acquisition | +3,661 | -- |
| 2026-06-24 | Kenneth Buechler | Independent Non-Executive Chairperson | Other Derivative Acquisition | +12,204 | -- |
| 2026-06-24 | Kenneth Buechler | Independent Non-Executive Chairperson | Other Derivative Acquisition | +15,532 | -- |
| 2026-06-24 | Edward Michael | Independent Director | Other Derivative Acquisition | +1,053 | -- |
| 2026-06-24 | Edward Michael | Independent Director | Other Derivative Acquisition | +3,513 | -- |
| 2026-06-24 | Edward Michael | Independent Director | Other Derivative Acquisition | +15,532 | -- |
| 2026-06-24 | Mary Polan | Independent Director | Other Derivative Acquisition | +1,664 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
昆德尔奥索诊断 讨论区 0 条评论